<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
        <PMID Version="1">22291464</PMID>
        <DateCompleted>
            <Year>2012</Year>
            <Month>10</Month>
            <Day>02</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2020</Year>
            <Month>09</Month>
            <Day>28</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1177-5491</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>6</Volume>
                    <PubDate>
                        <Year>2012</Year>
                    </PubDate>
                </JournalIssue>
                <Title>Biologics : targets &amp; therapy</Title>
                <ISOAbbreviation>Biologics</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Eribulin mesylate in the treatment of metastatic breast cancer.</ArticleTitle>
            <Pagination>
                <MedlinePgn>21-9</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.2147/BTT.S19811</ELocationID>
            <Abstract>
                <AbstractText>The treatment of metastatic breast cancer (MBC) has become increasingly challenging as the primary goals of therapy include prolonging life without added toxicity. While multiple agents are approved for the therapy of MBC, there is no standard approach for therapy beyond the second-line. Eribulin mesylate, an analog of the marine sponge halichondrin B, is a non-taxane microtubule dynamics inhibitor with a mechanism of action distinct from other tubulin-targeted drugs. Based on a significant extension in overall survival seen in a Phase III clinical trial, eribulin was approved for third-line therapy in MBC patients following anthracycline and taxane failure. Eribulin has a manageable toxicity profile and a low incidence of peripheral neuropathy. In this review, we discuss the natural source of eribulin, pharmacology, mode of action, preclinical and clinical data, and patient-focused perspectives.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Jain</LastName>
                    <ForeName>Sarika</ForeName>
                    <Initials>S</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Medicine, Weill Cornell Medical College, New York, NY, USA.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Cigler</LastName>
                    <ForeName>Tessa</ForeName>
                    <Initials>T</Initials>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2012</Year>
                <Month>01</Month>
                <Day>01</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>New Zealand</Country>
            <MedlineTA>Biologics</MedlineTA>
            <NlmUniqueID>101321511</NlmUniqueID>
            <ISSNLinking>1177-5475</ISSNLinking>
        </MedlineJournalInfo>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="N">eribulin</Keyword>
            <Keyword MajorTopicYN="N">metastatic breast cancer</Keyword>
            <Keyword MajorTopicYN="N">microtubule</Keyword>
        </KeywordList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2012</Year>
                <Month>2</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>1</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">22291464</ArticleId>
            <ArticleId IdType="doi">10.2147/BTT.S19811</ArticleId>
            <ArticleId IdType="pii">btt-6-021</ArticleId>
            <ArticleId IdType="pmc">PMC3266863</ArticleId>
        </ArticleIdList>
        <ReferenceList>
            <Reference>
                <Citation>J Natl Cancer Inst. 2008 Aug 20;100(16):1179-83</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18695137</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Jul 10;28(20):3256-63</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20530276</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2004 Aug 15;64(16):5760-6</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">15313917</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2005 Jul;4(7):1086-95</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16020666</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2010 Sep 1;28(25):3922-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20679609</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2001 Feb 1;61(3):1013-21</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">11221827</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Biochemistry. 2009 Aug 25;48(33):7927-38</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19586046</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21296855</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Mol Cancer Ther. 2008 Jul;7(7):2003-11</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18645010</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jun 15;15(12):4213-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19509146</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet Oncol. 2011 Oct;12(11):1045-52</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21937277</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Lancet. 2011 Mar 12;377(9769):914-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21376385</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Biol Chem. 1991 Aug 25;266(24):15882-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">1874739</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2007 Nov 20;25(33):5210-7</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">17968020</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Cancer Res. 2009 Jun 15;15(12):4207-12</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19509177</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Breast Cancer. 2010 Apr;10(2):160-3</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20299316</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Res. 2011 Jun 1;71(11):3952-62</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21498637</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Clin Lung Cancer. 2012 Jan;13(1):31-8</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">21862415</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">20610543</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Invest New Drugs. 2013 Apr;31(2):381-9</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">22555773</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2002 Jun 15;20(12):2812-23</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">12065558</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>Cancer Chemother Pharmacol. 2008 Sep;62(4):707-16</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">18431572</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2009 Jun 20;27(18):2954-61</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">19349550</ArticleId>
                </ArticleIdList>
            </Reference>
            <Reference>
                <Citation>J Clin Oncol. 2006 Apr 1;24(10):1633-42</Citation>
                <ArticleIdList>
                    <ArticleId IdType="pubmed">16575015</ArticleId>
                </ArticleIdList>
            </Reference>
        </ReferenceList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
